1.Effect of Prenatal and Postnatal Prophylaxis with Macrolide for Ureaplasma on the Development of Bronchopulmonary Dysplasia in Preterm Infants.
Euiseok JUNG ; Suyeong KIM ; Young Hwa JUNG ; Juyoung LEE ; Seung Han SHIN ; Chang Won CHOI ; Ee Kyung KIM ; Han Suk KIM ; Beyong Il KIM ; Jung Hwan CHOI
Neonatal Medicine 2015;22(2):78-83
PURPOSE: We aimed to evaluate the effects of two different macrolide prophylaxis protocols (prenatal and postnatal) for Ureaplasma on the development of bronchopulmonary dysplasia (BPD). METHODS: We retrospectively reviewed the medical charts of 121 preterm infants whose birth weights were <1,250 g or gestational ages were <30 postmenstrual weeks. The demographic and clinical characteristics, including the presence of BPD, were compared between a prophylactic group, who received macrolide as prophylaxis prenatally and postnatally according to risk level, and a confirmed treatment group, who received macrolide prenatally and postnatally after detection of Ureaplasma infection. RESULTS: Seventy-four (61.2%) of 121 preterm infants were included in the prenatal prophylaxis group. No significant differences in demographic characteristics were observed between the prenatal prophylaxis and prenatal confirmed treatment group. The detection rate of Ureaplasma and the frequency of postnatal therapeutic treatment with macrolide were lower in the prenatal prophylaxis group than in the prenatal confirmed treatment group (16.2% vs. 40.4%, P=0.003; 8.1% vs. 48.9%, P< 0.001, respectively). Although no significant differences in the incidence of moderate to severe BPD, the rate of severe BPD was lower in the prenatal prophylaxis group than in prenatal confirmed treatment group (18.9% vs. 40.4%, P=0.010). No significant differences in the incidences of BPD of any level of severity were observed between the postnatal prophylaxis and confirmed treatment groups. CONCLUSION: Administration of prenatal prophylaxis with macrolide decreased the detection rate of Ureaplasma after birth and was associated with the decrease in the incidence of severe BPD in preterm infants.
Birth Weight
;
Bronchopulmonary Dysplasia*
;
Gestational Age
;
Humans
;
Incidence
;
Infant
;
Infant, Newborn
;
Infant, Premature*
;
Macrolides
;
Parturition
;
Retrospective Studies
;
Ureaplasma Infections
;
Ureaplasma*
2.Three Cases of Preterm Infants Showing Pneumatosis Intestinalis without Progression to Typical Necrotizing Enterocolitis.
Eui Kyung CHOI ; Hyerim KIM ; Jung Yoon CHOI ; Suyeong KIM ; Euiseok JUNG ; Juyoung LEE ; Chang Won CHOI ; Beyong Il KIM
Neonatal Medicine 2014;21(3):192-197
Necrotizing enterocolitis (NEC) is a major gastrointestinal disorder in premature infants associated with high morbidity and mortality rates. When NEC is clinically suspected, radiological and laboratory studies should be performed to confirm the diagnosis and to aid in the management of patients. As the clinical manifestations of NEC are usually nonspecific, diagnoses are often made using abdominal radiographic findings, such as pneumatosis intestinalis. Clinicians typically consider the presence of pneumatosis intestinalis on radiographs as the definite evidence of stage II NEC. Here, we report 3 cases of preterm infants who had radiographic findings of pneumatosis intestinalis but did not have any other associated laboratory and clinical evidence of NEC, except bloody stools. The infants' systemic manifestations were mild or absent, and all of them completely recovered within 2-3 days, as demonstrated by the resolution of pneumatosis intestinalis on abdominal radiographs. The combination of hematochezia and intestinal pneumatosis in preterm infants strongly suggests the diagnosis of NEC. In our cases, there was no laboratory evidence of inflammation or platelet consumption, and the clinical course was benign without any sings of surgical abdomen. Additionally, our patients had barium-induced colitis or milk protein allergy, which are other possible causes of pneumatosis intestinalis. Because pneumatosis intestinalis can result from causes other than NEC, it is important to consider clinical, laboratory, and radiological findings to confirm the diagnosis of NEC.
Abdomen
;
Blood Platelets
;
Colitis
;
Diagnosis
;
Enterocolitis, Necrotizing*
;
Gastrointestinal Hemorrhage
;
Humans
;
Hypersensitivity
;
Infant, Newborn
;
Infant, Premature*
;
Inflammation
;
Milk Proteins
;
Mortality
3.GABA-enriched fermented Laminaria japonica improves cognitive impairment and neuroplasticity in scopolamine- and ethanol-induced dementia model mice.
Storm N S REID ; Je kwang RYU ; Yunsook KIM ; Byeong Hwan JEON
Nutrition Research and Practice 2018;12(3):199-207
BACKGROUND/OBJECTIVES: Fermented Laminaria japonica (FL), a type sea tangle used as a functional food ingredient, has been reported to possess cognitive improving properties that may aid in the treatment of common neurodegenerative disorders, such as dementia. MATERIALS/METHODS: We examined the effects of FL on scopolamine (Sco)- and ethanol (EtOH)-induced hippocampus-dependent memory impairment, using the Passive avoidance (PA) and Morris water maze (MWM) tests. To examine the underlying mechanisms associated with neuroprotective effects, we analyzed acetylcholine (ACh) and acetylcholinesterase (AChE) activity, brain tissue expression of muscarinic acetylcholine receptor (mAChR), cAMP response element binding protein (CREB) and extracellular signal-regulated kinases 1/2 (ERK1/2), and immunohistochemical analysis, in the hippocampus of mice, compared to current drug therapy intervention. Biochemical blood analysis was carried out to determine the effects of FL on alanine transaminase (ALT), aspartate transaminase (AST), and triglyceride (TG) and total cholesterol (TC) levels. 7 groups (n = 10) consisted of a control (CON), 3 Sco-induced dementia and 3 EtOH-induced dementia groups, with both dementia group types containing an untreated group (Sco and EtOH); a positive control, orally administered donepezil (Dpz) (4mg/kg) (Sco + Dpz and EtOH + Dpz); and an FL (50 mg/kg) treatment group (Sco + FL50 and EtOH + FL50), orally administered over the 4-week experimental period. RESULTS: FL50 significantly reduced EtOH-induced increase in AST and ALT levels. FL50 treatment reduced EtOH-impaired step-through latency time in the PA test, and Sco- and EtOH-induced dementia escape latency times in the MWM test. Moreover, anticholinergic effects of Sco and EtOH on the brain were reversed by FL50, through the attenuation of AChE activity and elevation of ACh concentration. FL50 elevated ERK1/2 protein expression and increased p-CREB (ser133) in hippocampus brain tissue, according to Western blot and immunohistochemistry analysis, respectively. CONCLUSION: Overall, these results suggest that FL may be considered an efficacious intervention for Sco- and EtOH-induced dementia, in terms of reversing cognitive impairment and neuroplastic dysfunction.
Acetylcholine
;
Acetylcholinesterase
;
Alanine Transaminase
;
Animals
;
Aspartate Aminotransferases
;
Blotting, Western
;
Brain
;
Cholesterol
;
Cognition Disorders*
;
Cyclic AMP Response Element-Binding Protein
;
Dementia*
;
Drug Therapy
;
Ethanol
;
Extracellular Signal-Regulated MAP Kinases
;
Functional Food
;
Hippocampus
;
Immunohistochemistry
;
Laminaria*
;
Memory
;
Mice*
;
Neurodegenerative Diseases
;
Neuronal Plasticity*
;
Neuroprotective Agents
;
Receptors, Muscarinic
;
Scopolamine Hydrobromide
;
Triglycerides
;
United Nations
;
Water
4.Comparison of Clinical Outcomes of Long Stent Implantation with First- and Second-Generation Drug-Eluting Stents Following Rotational Atherectomy
Dongeon KIM ; Suyeong PARK ; Inki MOON ; Min Gyu KONG ; Hyun Woo PARK ; Hyung Oh CHOI ; Hye-Sun SEO ; Jon SUH ; Nae-Hee LEE ; Yoon Haeng CHO
Soonchunhyang Medical Science 2022;28(1):15-22
Objective:
Rotational atherectomy (RA) and newly developed second-generation drug-eluting stent (DES) support the strategy of longer stent deployment in comparison to short stent implantations in the past. However, studies analyzing the outcome of patients who received long stent implantation following RA are few in number. The present study compared the clinical outcomes of patients with the coronary arterial disease (CAD) who underwent RA with long stent implantation using first- and second-generation DES.
Methods:
A retrospective cohort study was performed at the single center from March 2003 to October 2019. Eighty-seven patients with CAD who underwent RA with ≥32 mm long stent implantation were enrolled in the study and divided into two groups according to the type of DES. As a primary endpoint, the cumulative 2-year incidence of major adverse cardiac events (MACE) including death, myocardial infarction (MI), target vessel revascularization, and stent thrombosis (ST) was compared by DES type. Adjusted interaction between the type of stent and clinical variables was estimated to determine the predictor variables of MACE.
Results:
The second-generation DES group was associated with a shorter procedure duration and more common usage of intravascular ultrasound in procedural characteristics. In the second-generation DES group, a trend toward a lower rate of MI and ST existed. All-cause mortality and cardiovascular mortality were not significantly different. When combined with MACE, we could identify a significant reduction in the second-generation DES group.
Conclusion
In comparison to the first-generation DES group, the second-generation DES group was associated with a lower rate of MACE for 2 years in patients who underwent RA with long stent implantation.
5.Outpatient Follow-up Status and Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants.
Suyeong KIM ; In Gu SONG ; Kyu lee KIM ; Yoon Joo KIM ; Seung Han SHIN ; Seung Hyun LEE ; Jae Myung LEE ; Juyoung LEE ; Jin A SOHN ; Hyun Ju LEE ; Jin A LEE ; Chang Won CHOI ; Ee Kyung KIM ; Han Suk KIM ; Byeong Il KIM ; Jung Hwan CHOI
Journal of the Korean Society of Neonatology 2012;19(1):17-25
PURPOSE: To report the follow-up status and neurodevelopmental outcomes of extremely low birth weight (ELBW) survivors at 18 months' corrected age (CA). METHOD: We performed a retrospective study of 130 ELBW infants admitted to neonatal intensive care unit of Seoul National University Children's Hospital between January 2005 and May 2009. The follow-up status and neurodevelopmental outcomes were evaluated until the CA of 18 months. The assessment of outcomes included cerebral palsy, cognitive developmental delay, blindness, deafness and catch-up growth. Clinical data were collected to identify the factors influencing neurodevelopmental disability. RESULTS: Of the 130 survivors at discharge, 122 (93.8%) participated in the follow-up at 18 months' CA. Study characteristics included a mean birth weight of 783 g and a mean gestation of 27 weeks. One hundred and eleven infants (85.4%) were evaluated for cerebral palsy (CP) and 11 (9.9%) were identified with CP. Eighty five infants (74.6%) were assessed with the Bayley Scales of Infant Development-III (BSID-III) at 8 months' CA and 2 (2.4%) had a cognitive scale <70. Fifty four infants (41.9%) were assessed with BSID-III at 18 months' CA and 2 (3.7%) had a cognitive scale <70. There were 2 (1.2%) cases of blindness and the case of deafness was not present in this study. The failure of catch-up growth was seen in 40 (32.8%) infants. Severe intraventricular hemorrhage, periventricular leukomalacia, hydrocephalus and shunt insertion were the most important risk factors for neurologic abnormality. CONCLUSION: In our institution, neurodevelopmental outcomes of ELBW survivors were comparable to recent reports from the USA. ELBW infants need to be monitored on multidisciplinary follow-up programs and more efforts should be made to improve the follow-up.
Birth Weight
;
Blindness
;
Cerebral Palsy
;
Deafness
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Hydrocephalus
;
Infant
;
Infant, Low Birth Weight
;
Infant, Newborn
;
Intensive Care, Neonatal
;
Leukomalacia, Periventricular
;
Outpatients
;
Pregnancy
;
Retrospective Studies
;
Risk Factors
;
Survivors
;
Weights and Measures
6.Temporal Trend of the Incidence and Characteristics of Renal Infarction:Korean Nationwide Population Study
Dong-Eon KIM ; Inki MOON ; Suyeong PARK ; Minae PARK ; Sojeong PARK ; Seong Soon KWON ; Min Gyu KONG ; Hyun Woo PARK ; Hyung Oh CHOI ; Hye-Sun SEO ; Yoon Haeng CHO ; Nae Hee LEE ; Jon SUH
Journal of Korean Medical Science 2023;38(31):e239-
Background:
Large-scale studies about epidemiologic characteristics of renal infarction (RI) are few. In this study, we aimed to analyze the incidence and prevalence of RI with comorbidities in the South Korean population.
Methods:
We investigated the medical history of the entire South Korean adult population between 2013 and 2019 using the National Health Insurance Service database (n = 51,849,591 in 2019). Diagnosis of RI comorbidities were confirmed with International Classification of Disease, Tenth Revision, Clinical Modification codes. Epidemiologic characteristics, distribution of comorbidities according to etiologic mechanisms, and trend of antithrombotic agents were estimated.
Results:
During the 7-years, 10,496 patients were newly diagnosed with RI. The incidence rate increased from 2.68 to 3.06 per 100,000 person-years during the study period.The incidence rate of RI increased with age peaking in the 70s with 1.41 times male predominance. The most common comorbidity was hypertension, followed by dyslipidemia and diabetes mellitus. Regarding etiologic risk factor distribution, high embolic risk group, renovascular disease group, and hypercoagulable state group accounted for 16.6%, 29.1%, and 13.7% on average, respectively. For the antithrombotic treatment of RI, the prescription of antiplatelet agent gradually decreased from 17.0% to 13.0% while that of anticoagulation agent was maintained around 35%. The proportion of non-vitamin K antagonist oral anticoagulants remarkably increased from only 1.4% to 17.6%.
Conclusion
Considering the progressively increasing incidence of RI and high prevalence of coexisting risk factors, constant efforts to raise awareness of the disease are necessary. The current epidemiologic investigation of RI would be the stepping-stone to establishing future studies about clinical outcomes and optimal treatment strategies.